Efficacy of different concentrations of lidocaine and association of vasoconstrictor in local infiltration anesthesia in adults

Dear Editor,

Local infiltration anesthesia blocks nerve conduction without causing central nervous system depression. In dermatological surgeries, lidocaine is the most widely used anesthetic worldwide; however, its toxicity is dose-dependent, limiting the use of higher volumes in larger surgeries.1,2

In Brazil, the lidocaine concentration predominantly used in dermatological procedures is 2%, with the association of vasoconstrictors, such as epinephrine, aiming to reduce intraoperative bleeding, prolong the anesthetic effect, in addition to delaying its systemic absorption, allowing the use of higher volumes, with a lesser risk of toxicity.3

Cutaneous infiltration of these solutions is associated with some discomfort. Thus, it is important to study strategies to minimize the patient’s pain during anesthesia, favoring their collaboration, promoting greater anesthetic success, in addition to humanizing the procedure.4

Warming up the anesthetic solution, slow and subcutaneous infiltration, alkalization of the solution, previous use of a topical anesthetic, thinner needles, hypnotherapy, pre-anesthetic medications, skin vibration, and cooling, are some well-described strategies aimed at minimizing the pain associated with local infiltration anesthesia.2–5 However, there have been few systematic studies reporting on the concentrations of lidocaine and epinephrine related to the painful sensitivity of the infiltration and its effectiveness in dermatological procedures.6

The aim of this study was to evaluate lidocaine concentrations and their association with vasoconstrictors related to the duration of anesthesia and pain due to intradermal infiltration in the forearm of adult patients.

For this purpose, a double-blind experimental model was used, involving ten adult volunteers. The project was approved by the institution’s Research Ethics Committee (n. 2,647,476), and all participants signed the informed consent form. Adult patients (aged >18 years) were included, without forearm dermatoses, hypersensitivity to lidocaine, acrophobia, or coagulation disorders.

After antisepsis, the following solutions were injected slowly intradermally by the same dermatologist: 0.1 mL of a 0.5%, 1.0%, or 2% lidocaine solution with and without epinephrine (1: 200,000), and NaCl 0.9% (control), in a blinded and randomized design, on the ventral surface of the forearm. Insulin syringes (BD-ultrafine) were used. All ten participants received all seven treatments, in a randomized sequence.

Pain intensity related to the infiltration of each solution was assessed using a visual analog scale (VAS: 0–10 points). Subsequently, the presence of pain was evaluated at the standardized puncture with lancets used in the prick test for capillary blood glucose (5 mm), using a specific pen, at

References

1. Leonardi GC, Falzone L, Salemi R, Zanghi A, Spandidos DA, Mccubrey J, et al. Cutaneous Melanoma: From Pathogenesis to Therapy. Int J Oncol. 2018;52:1071–80.
2. Apalla Z, Lallas A, Sotiriou E, Lazaridou I, Iaonides D. Epidemiological trends in skin cancer. Dermatol Pract and Concept. 2017;7:1–6.
3. Farahi JM, Fazzari M, Braunberger T, Caravaglio JV, Kretowicz A, Wells K, et al. Gender differences in melanoma prognostic fator. Dermatol Online J. 2018;24:2–8.
4. Criado PR, Vasconcellos C, Sittart JAS, Valente NYS, Moura BPS, Barbosa GL, et al. Melanoma maligno cutâneo primário: estudo retrospectivo de 1963 a 1997 no Hospital do Servidor Público Estadual de São Paulo. Rev Ass Med Brasil. 1999;45:157–62.
5. Joose A, van der Ploeg APT, Haydu LE, Nijsten TEC, de Vries E, Scolyer RA, et al. Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. Ann Surg Oncol. 2015;22:1598–603.
6. Crocetti E, Fancelli L, Manneschi G, Caldarella A, Pimpinelli N, Chiarugi A, et al. Melanoma survival: sex does matter, but we do not know how. Eur J Cancer Prev. 2016;25:404–9.
7. El Sharouni MA, Witkamp AJ, Sigurdsson V, Van Diest PJ, Louwman MWJ, Kukutsch NA. Sex matters: men with melanoma have a worse prognosis than women. J Eur Acad Dermatol Venereol. 2019;33:2062–7.
8. Joosse A, de Vries E, van Eijck CH, Eggermont AMM, Nijsten T, Coebergh JWW. Pigment Cell Melanoma Res. 2010;23:352–64.

* Corresponding author.
E-mail: dhenriquems@gmail.com (D.H. Morais Silva).

Received 7 July 2020; accepted 20 August 2020
Available online 18 July 2021

https://doi.org/10.1016/j.abd.2020.08.022
0365-0569/ © 2021 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).
Our 30 vs painful concentration comparisons while receiving lidocaine and epinephrine in a manner, according to the ten participants and the evaluation time. The infiltration of painful sensitivity at different times were compared regarding the effect of lidocaine concentration, use of epinephrine and the drug interaction through generalized linear models of mixed-effects (normal distribution and logit), with an unstructured covariance matrix, and Sidak’s post hoc test. A p-value of ≤ 0.05 was considered significant. The sample size was based on the expectation of a difference > 30% in the proportion of pain by any of the compositions, with an alpha error = 0.05 and beta = 0.2.

Of the study volunteers, 5 (50%) were females, with ages ranging from 20 to 43 years. The pain scores resulting from the intradermal infiltration of each solution are shown in Fig. 1. There was a slight increase in the mean infiltration pain score in the participants who received epinephrine, compared to those who did not receive it (5.8 [sd = 2.1] vs 5.0 [sd = 2.2]; p = 0.013). Similarly, higher infiltration pain scores were observed in participants who received high concentrations of lidocaine (2%), when compared to those receiving lower concentrations (1% and 0.5%) concentrations (6.6 [sd = 1.7] vs. 5.1 [sd = 2.1] and 4.5 [sd = 1.8]; p < 0.001).

The frequencies of painful sensitivity after the standardized stimulus for each anesthetic solution, are shown in Fig. 2. There was no painful sensitivity with the 2% lidocaine solution with epinephrine throughout the experiment, while the other solutions maintained anesthesia for up to 30 min in all cases. The painful sensitivity progressed in relation to time and was inversely proportional to the lidocaine concentration (p < 0.001); similarly, the anesthesia lasted longer when epinephrine was used (p = 0.046). The post hoc analysis showed that, between 0 and 45 min, there was no difference in the anesthetic profile for 2% and 0.5% lidocaine (p > 0.15).

Fig. 3 shows the frequency of sensitivity to an intense painful stimulus after 60 min of the infiltration of each solution. None of the participants had pain in the region where 2% lidocaine was infiltrated with epinephrine. A lower frequency of sensitivity was observed in the solutions that used epinephrine (30% vs. 70%; p < 0.001), as well as, proportionally, in the solutions that used the highest concentrations of lidocaine (0.5%; 1% and 2%): 38% vs. 27% vs. 8% (p < 0.001). A positive interaction between epinephrine and lidocaine was identified at a concentration of 1% (40% vs. 80%; p = 0.035), whereas a negligible significance was observed for the interaction with 2% lidocaine (0% vs. 60%; p = 0.070).

Pain related to the process of local anesthetic infiltration is associated with elements related to the patient, the application technique and the used solutions. Our results showed different behaviors regarding the effectiveness and pain of infiltration when the concentrations of lidocaine and associated epinephrine varied.

Figure 1 Pain intensity (VAS - Visual Analogue Scale: 0–10) reported at the time of the injections of the different tested solutions (n = 70).

Figure 2 Frequency of painful sensation (standardized stimulus) in relation to time, after injections of the different tested solutions (n = 350).
The association of epinephrine and lidocaine rati- 
ofed its effect by extending the duration of anesthetic 
effectiveness. The increase of pain in the infiltration asso-
ociated with epinephrine can be compensated, for instance, 
with lower concentrations of lidocaine, or alkalization tech-
niques, such as the addition of bicarbonate, without 
impairing the anesthetic effect.

Lidocaine at concentrations lower than 2% also showed 
no difference in the anesthetic profile of the first 30 min, 
confirming the results from the tumescent anesthesia 
technique. Lower concentrations of lidocaine, when 
associated with epinephrine, increase the safety of anes-
thesia, especially when larger volumes of anesthetics are 
needed.

The study has some limitations associated with its expe-
imental characteristic, which does not consider the anxiety 
that is naturally involved in dermatological surgeries, in 
addition to the reduced volume of anesthetic used. In con-
trast, the intradermal injection promotes a faster effect, 
with more pain at the injection. Finally, the use of only 
one topography hampers the generalization of the results 
to other areas with greater sensory innervation, such as 
the face. All of these elements have been standardized aiming 
to maximize the comparability of individuals.

In conclusion, lidocaine, at concentrations of 0.5% or 
1%, promotes less pain at intradermal infiltration without 
anesthetic impairment in the first 30 min, and epinephrine 
increases the effectiveness and duration of local anesthesia.

Financial support

None declared.

Authors’ contributions

Lury Bueno Wako Kitahara: Data collection; writing of the 
text; literature review; final approval of the manuscript.

Vanessa Paula da Silva: Data collection; writing of the 
text; literature review; final approval of the manuscript.

Gabriel Peres: Data collection; project concept; data 
analysis; writing of the text; literature review; final approval 
of the manuscript.

Hélio Amante Miot: Data collection; project concept; data 
analysis; writing of the text; literature review; final approval 
of the manuscript.

Juliano Vilaverde Schmitt: Data collection; project 
concept; data analysis; writing of the text; literature 
review; final approval of the manuscript.

Conflicts of interest

None declared.

Acknowledgments

None declared.

References

1. Kouba DJ, LoPiccolo MC, Alam M, Bordeaux JS, Cohen B, 
Hanke CW, et al. Guidelines for the use of local anesthesia 
in office-based dermatologic surgery. J Am Acad Dermatol. 
2016;74(1):1201–19.

2. Cherobin A, Tavares GT. Safety of local anesthetics. An Bras 
Dermatol. 2020;95:82–90.

3. Quaba O, Huntley JS, Bahia H, McKeown DW. A users guide for 
reducing the pain of local anaesthetic administration. Emerg 
Med J. 2005;22:188–9.

4. Bell RW, Butt ZA, Gardner RF. Warming lignocaine reduces 
the pain of injection during local anaesthetic eyelid surgery. Eye 
(Lond). 1996;10:558–60.

5. Schmitt JV, Miot HA. Randomized, double-blind, controlled top-
ical anesthesia induced by iontophoresis of lidocaine. Surg Cosm 
Dermatol. 2009;3:112–4.

6. Morganroth PA, Gelfand JM, Jambusaria A, Margolis DJ, Miller 
CJ. A randomized, double-blind comparison of the total dose 
of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lido-
caine with 1:200,000 epinephrine required for effective local 
anesthesia during Mohs microscopic surgery for skin cancers. J 
Am Acad Dermatol. 2009;60:444–52.

7. Chow MY, Sia AT, Koay CK, Chan YW. Alkalization of lidocaine 
does not hasten the onset of axillary brachial plexus block. 
Anesth Analg. 1998;86:566–8.

8. Masters JE. Randomised control trial of pH buffered ligno-
caine with adrenaline in outpatient operations. Br J Plast Surg. 
1998;51:385–7.

9. Alam M, Ricci D, Havey J, Rademaker A, Witherspoon J, West 
PD. Safety of peak serum lidocaine concentration after Mohs 
micrographic surgery: a prospective cohort study. J Am Acad 
Dermatol. 2010;63:87–92.

10. Rozanski RJ, Primosch RE, Courts FJ. Clinical efficacy of 1 and 
2% solutions of lidocaine. Pediatr Dent. 1988;10:287–90.

Lury Bueno Wako Kitahara 🐦, Vanessa Paula da Silva 🐦, 
Gabriel Peres 🐦, Hélio Amante Miot 🐦, 
Juliano Vilaverde Schmitt 🐦

Faculty of Medicine, Universidade Estadual Paulista, 
Botucatu, SP, Brazil

*Corresponding author.
E-mail: heliomiot@gmail.com (H.A. Miot).

Received 17 May 2020; accepted 11 August 2020
Available online 16 July 2021

https://doi.org/10.1016/j.abd.2020.08.021
0365-0596/ © 2021 Sociedade Brasileira de Dermatologia.
Published by Elsevier España, S.L.U. This is an open access article 
under the CC BY license
(https://creativecommons.org/licenses/by/4.0/).